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Regions in b-Chemokine Receptors CCR5 and CCR2b
That Determine HIV-1 Cofactor Specificity
Joseph Rucker,*# Michel Samson,‡# 1996). Expression of this protein, termed Fusin (originally
termed 7TMS and also referred to as HUMSTR andBenjamin J. Doranz,*# Fre´de´rick Libert,‡#
LESTR), in conjunction with CD4 allows entry of T-tropicJoanne F. Berson,* Yanjie Yi,† Robert J. Smyth,†
viruses into cells (Berson et al., 1996; Choe et al., 1996;Ronald G. Collman,† Christopher C. Broder,‖
Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996;Gilbert Vassart,‡§ Robert W. Doms,*
Feng et al., 1996). In addition, cells expressing both CD4and Marc Parmentier†
and Fusin form syncytia with cells expressing T-tropic*Department of Pathology and Laboratory Medicine
env proteins. However, Fusin is not used as a cofactor†Pulmonary and Critical Care Division
by macrophage-tropic (M-tropic) isolates of HIV-1 (Ber-Department of Medicine
son et al., 1996; Choe et al., 1996; Deng et al., 1996;University of Pennsylvania
Doranz et al., 1996; Dragic et al., 1996; Feng et al., 1996),Philadelphia, Pennsylvania 19104
which are far more prevalent than T-tropic virus strains,‡ IRIBHN
particularly during the asymptomatic period of infection§Service de Ge´ne´tique Me´dicale
(Tersmette et al., 1988, 1989; Schuitemaker et al., 1991,Universite´ libre de Bruxelles, Campus Erasme
1992; Conner et al., 1993).808 route de Lennik
The relationship of Fusin to the chemokine receptors,B-1070 Bruxelles
coupled with the observation that the b-chemokinesBelgium
RANTES, MIP-1a, and MIP-1b inhibit entry of M-tropic,‖Department of Microbiology and Immunology
but not T-tropic,virus strains (Cocchi et al., 1995; PaxtonUniformed Services University of the Health Sciences
et al., 1996), led to the rapid identification of the4301 Jones Bridge Road
b-chemokine receptor CCR5 as the major entry cofactorBethesda, Maryland 20814-4799
for primary, M-tropic virus strains (Alkhatib et al., 1996;
Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996;
Dragic et al., 1996). CCR5, which is expressed in mono-Summary
cytes, macrophages, and primary T cells, binds to
RANTES, MIP-1a, and MIP-1b (Alkhatib et al., 1996;Macrophage-tropic (M-tropic) HIV-1 strains use the
Deng et al., 1996; Dragic et al., 1996; Samson et al.,b-chemokine receptor CCR5, but not CCR2b, as a
1996). Expression of CCR5 in conjunction with CD4 incofactor for membrane fusion and infection, while the
a variety of cell types renders them permissive for infec-dual-tropic strain 89.6 uses both. CCR5/2b chimeras
tion by M-tropic virus strains as well as for syncytiaand mutants were usedto map regions of CCR5 impor-
formation mediated by M-tropic env proteins (Choe ettant for cofactor function and specificity. M-tropic
al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragicstrains required either the amino-terminal domain or
et al., 1996). Other chemokine receptors can serve asthe first extracellular loop of CCR5. A CCR2b chimera
entry cofactors for certain virus strains, including CCR3containing the first 20 N-terminal residues of CCR5
and CCR2b (Choe et al., 1996; Doranz et al., 1996).supported M-tropic envelope protein fusion. Amino-
The identification of Fusin, CCR2b, CCR3, and CCR5terminal truncations of CCR5/CCR2b chimeras indi-
as entry cofactors for T- and M-tropic virus strains hascated that residues 2–5 are important for M-tropic
important implications for understanding the molecularviruses, while 89.6 is dependent on residues 6–9. The
basis of viral tropism and affords new opportunities foridentification of multiple functionally important re-
designing antiviralstrategies. It will be important tochar-gions in CCR5, coupled with differences in how CCR5
acterize regions of the chemokine receptors that areis used by M- and dual-tropic viruses, suggests that
involved in chemokine binding and env protein interac-interactions between HIV-1 and entry cofactors are
tions in order both to better understand the molecularconformationally complex.
basis of viral tropism and the molecular evolution of
HIV-1 strains as they change cofactor usage, and to
Introduction better design agents that might prevent cofactor utiliza-
tion by primary HIV strains. In addition, structure–
The entry of HIV-1 into target cells requires the participa- function studies of HIV-1 cofactors will be needed to
tion of at least two cell surface molecules. All HIV-1 understand the role these receptors play in viral entry
strains utilize CD4 as the primary virus receptor through and membrane fusion.
a high affinity interaction with the viral envelope (env) To identify regions in CCR5 that play a role in mem-
protein. However, CD4 alone is not sufficient for virus brane fusion mediated by a variety of M-tropic and dual-
entry: one or more additional cell surface molecules, tropic viruses, we constructed chimeric molecules
termed cofactors, are required (Maddon et al., 1986; based on CCR5 and CCR2b, the chemokine receptor to
Ashorn et al., 1990; Chesebro et al., 1990; Dragic et which CCR5 is most closely related (76% identity). We
al., 1992; Broder et al., 1993). Virus strains adapted for found that M-tropic viruses were most sensitive to
growth in transformed T cell lines (T-tropic) use the changes in the very N-terminal portion of the amino-
SDF-1 chemokine receptor as a cofactor (Feng et al., terminal domain and in the first extracellular loop. While
substitution of either domain with the corresponding
region of CCR2b was tolerated, substitution of both was# These authors contributed equally to this work.
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not. We found several chimeric molecules that could
function as cofactors for either M-tropic or dual-tropic
env proteins, but not both. Our results identify regions
in CCR5 required for cofactor function, indicate that
interactions between CCR5 and M- and dual-tropic vi-
ruses can differ and are structurally complex, and sug-
gest that the molecular evolution of virus strains for
growth in a given target cell population may involve
changes not only in the types of cofactors used, but
also in how a given cofactor is utilized.
Results
The b-Chemokine Receptors CCR5 and CCR2b
Support Fusion and Infection by Viruses
with Distinct Tropisms
Introduction of CCR5 in conjunction with human CD4
into otherwise nonpermissive cells renders them fully
permissive for M-tropic virus entry and for M-tropic env-
mediated syncytia formation. By contrast, expression
of CCR2b fails to render cells permissive for M-tropic
env-mediated syncytia formation (Choe et al., 1996;
Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996).
Figure 1. Ability of CCR5, CCR2b, and Fusin to Support env-Depen-However, the dual-tropic HIV-1 strain 89.6 was able to
dent Membrane Fusionfuse with cells expressing CD4 and either CCR2b or
(A) QT6 cells expressing CD4, the indicated cofactor, and luciferaseCCR5 (Doranz et al., 1996). Therefore, to identify regions
undercontrol of the T7 promoter were mixedwith HeLa cells infected
in CCR5 that are important for M-tropic strain cofactor with vaccinia virus vectors expressing eitherT-tropic (BH8), M-tropic
function, we constructed a series of chimeric molecules (JR-FL, ADA, SF162, or the clade E virus CM243), or dual-tropic
between CCR5 and CCR2b. This approach had two im- (89.6) env proteins. Effector cells were also infected with vTF1.1
(MOI 5 10), which expresses T7 polymerase under the control ofportant advantages. First, construction of chimeras be-
the vaccinia late promoter. Cells were allowed to fuse for 6–8 hrtween two closely related molecules is more likely to
before lysis in Reporter Lysis Buffer (Promega) and assay for lucifer-result in proper folding and transport to the cell surface
ase activity. Results are expressed in terms of relative light units(Doms et al., 1993). Second, since 89.6 uses both cofac-
(RLU).
tors, we anticipated that CCR5/2b chimeras would likely (B) QT6 cells expressing CD4 alone (1) or with CCR2b (2) or CCR5
function as cofactors for 89.6. Thus, 89.6 could serve (3) were infected with HIV-1 strains JR-FL, 89.6, or mock superna-
tant. The following day, cells were lysed and HIV reverse transcrip-as a positive control for cell surface expression.
tion products were detected by PCR amplification of U3/U5 se-Prior to generating chimeric molecules, we extended
quences followed by Southern blot. HIV-1 plasmid (P) served as aour earlier observations by testing the ability of CCR5
positive control.and CCR2b to function as cofactors for additional
M-tropic viruses. To measure syncytia formation, we
used a luciferase-based gene reporter assay (Doranz et
We also tested the ability of CCR2b to function as aal., 1996). In this assay, HeLa cells are infected with
cofactor for virus infection. QT6 cells expressing CD4recombinant vaccinia virus vectors expressing the env
alone or in combination with CCR5 or CCR2b were in-protein of interest and the T7 RNA polymerase. Quail
fected with either 89.6 or JR-FL. To detect virus entryQT6 cells are transfected with plasmids encoding CD4,
24 hr later, we used a PCR-based entry assay to detectthe desired cofactor, and the luciferase gene under con-
early viral DNA transcripts. We found that CCR2b sup-trol of the T7 promoter. QT6 cells were chosen as targets
ported entry by 89.6 but not by JR-FL (Figure 1B). Thusbecause expression of CD4 alone fails to render them
CCR2b served as a fusion and infection cofactor forpermissive for env-mediated membrane fusion and be-
89.6 but not for the M-tropic strains tested here.cause they are easily transfected. Fusion between the
target and effector cells results in T7 polymerase-depen-
dent luciferase expression, making this a sensitive and
The N-Terminus of CCR5 Is Sufficient but Notquantitative cell–cell fusion assay. We found that HeLa
Necessary for JR-FL env-Mediated Fusioncells expressing the env proteins derived from the
To identify regions of CCR5 that are required for cofactorM-tropic strains JR-FL, ADA, and SF162, together with
function, a series of chimeric molecules was generatedthe clade E strain CM243, readily fused with QT6 cells
in which individual extracellular domains of CCR2b wereexpressing CD4 and CCR5 (Figure 1A). Fusion was not
replaced with the corresponding regions of CCR5. Inobserved when either Fusin or CCR2b was used in place
this way, we could determine whether any single regionof CCR5. By contrast, the env protein derived from the
of CCR5 could confer M-tropic cofactor activity todual-tropic virus strain 89.6 formed syncytia with cells
CCR2b. Chimeric molecules were created by utilizingexpressing either Fusin, CCR2b, or CCR5 in conjunction
with CD4, as previously reported (Doranz et al., 1996). common restriction sites in regions conserved between
CCR5 Determinants of Cofactor Specificity
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with CD4 in QT6 cells and then mixed with HeLa cells
expressing either the 89.6 or the JR-FL env proteins. As
shown in Figure 2B, substitution of the amino-terminal
domain and first transmembrane segment of CCR2b
with the corresponding region of CCR5 resulted in a
chimera that supported fusion by both the JR-FL and
89.6 env proteins. We also note that this chimera (C25-
06) has no potential N-linked glycosylation sites, indi-
cating that N-linked glycosylation is not required for
cofactor function. Indeed, elimination of the N-linked
glycosylation site in CCR5 by site-directed mutagenesis
had no effect on cofactor function (data not shown).
Replacement of the second or third extracellular loops
of CCR2b with those from CCR5 failed to support JR-
FL mediated membrane fusion. However, both of these
chimeras (C25-14 and C25-03) supported fusion medi-
ated by 89.6, indicating that they were expressed on
the cell surface. One chimera, C25-10, failed to support
fusion by either JR-FL or 89.6. Since the 89.6 env protein
can fuse with cells expressing CD4 and either CCR5 or
CCR2b, we think it most likely that this chimera is not
expressed at the cell surface, perhaps due to a folding
defect. Development of specific antisera will make it
possible to measure surface expression of this and other
chimeric molecules.
The results with the first set of chimeric molecules
indicated that the amino terminus of CCR5, when intro-
duced into a CCR2b background, was sufficient to con-
fer M-tropic cofactor activity to CCR2b. To determine
whether the amino-terminal domain of CCR5 was re-
Figure 2. CCR2b Chimeras with Single CCR5 Domain Replace- quired for cofactor activity, we sequentially replaced
ments
each extracellular domain of CCR5 with the correspond-
(A) The structures of CCR5, CCR2b, and chimeras containing single- ing region of CCR2b (Figure 3A). Somewhat surprisingly,
domain swaps of CCR5 into CCR2b are represented schematically.
we found that no single extracellular domain of CCR5The junctions between chimeric segments correspond to the AflII,
is required for cofactor function when replaced with theClaI, and EcoRI sites represented in the parental structures. The
putative N-linked glycosylation sites originating from CCR2b and homologous domain from the CCR2b receptor (Figure
CCR5 are represented when present in the constructs. The pheno- 3B). However, the amino-terminal domain appears to
type for each construct with regards to enabling fusion for JR- play an important role in cofactor function as it is suffi-
FL and 89.6, respectively, is shown for convenience above each
cient to confer M-tropic cofactor activity to CCR2b. Thatconstruct in parenthesis. (1,1) indicates that the molecule sup-
it is not absolutely required for cofactor function indi-ported fusion by both env proteins, while (2,1) indicates fusion for
cates that one or more additional domains of CCR5 play89.6 alone.
(B) QT6 cells expressing CD4, the indicated cofactor, and luciferase an important role in virus entry and membrane fusion.
under control of the T7 promoter were mixed with HeLa cells ex-
pressing the T7 polymerase and the indicated env protein. The de-
gree of cell–cell fusion was determined by measuring relative light N-Terminal Domain Truncations Differentiate
units 8 hr after mixing, as in Figure 1. 89.6 and JR-FL Cofactor Usage
To further delineate the region of the CCR5 amino termi-
nus that is critical for cofactor function, we constructedthe two molecules (Figure 2A). This approach also re-
sulted in substitution of CCR2b transmembrane and cy- a series of CCR5 molecules containing sequential four–
amino acid deletions after the N-terminal methioninetoplasmic domains with those from CCR5. However, as
shown in Figure 8, the transmembrane domains of CCR5 (Figure 3A). We found that elimination of the first eight
residues from the mature molecule (i.e., after the initiatorand CCR2b are highly conserved (89% identity, includ-
ing all seven proline residues), as are the three intracellu- methionine) had no effect on JR-FL or 89.6 env-medi-
ated syncytia formation (Figure 3B). However, removallar loops (92% identity). Including highly conservative
amino acid substitutions, the degree of similarity be- of an additional four or eight residues blocked fusion
by 89.6 but not by JR-FL. Thus 89.6 is more sensitivetween the transmembrane and intracellular loops of
CCR5 and CCR2b is 95% and 96%, respectively. By to truncations in the amino-terminal domain of CCR5
than is the M-tropic strain JR-FL, indicating that differentcontrast, the extracellular domains of CCR5 and CCR2b
share only 45% amino acid identity. Thus the amino- env proteins can utilize the same cofactor in different
ways.terminal domain and extracellular loops are likely to play
the major role in determining the cofactor phenotypes Since regions of CCR5 other than the N-terminal do-
main can also allow fusion by JR-FL (Figure 3), we rea-exhibited by the chimeric molecules.
The chimeras, depicted in Figure 2A, were expressed soned that truncations of the CCR5 amino terminus
Cell
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Figure 3. CCR5 Chimeras with Single CCR2b Domain Replace-
ments and N-Terminal CCR5 Truncations
(A) The structures of four chimeric molecules containing single-
Figure 4. Truncated CCR5 Amino-Terminal Domain Chimerasdomain exchanges of CCR2b (light shading) into CCR5 (dark shad-
ing) are shown in the top row, and a series of N-terminal CCR5 (A) The following chimeric molecules are depicted: C25-21, lacking
deletions are shown in the second row, in which 4, 8, 12, or 16 the first four residues of the CCR5 amino terminus; C25-22, lacking
residues were deleted, respectively. The ability of each construct the first eight residues of CCR5; C25-28, in which the first 20 residues
to support fusion for JRFL and 89.6, respectively, is shown above of CCR5 are in a CCR2b background; C25-25, in which the first 20
each construct in parentheses. residues of CCR2b are in a CCR5 background; and C25-26, in which
(B) Fusion of QT6 cells expressing CD4 and the indicated cofactor the first 20 residues of CCR5 are followed by the rest of the CCR2b
or chimera with HeLa cells expressing the JR-FL or 89.6 env proteins amino-terminal domain, the first transmembrane domain of CCR2b,
was determined using the luciferase reporter assay as shown in and the rest of CCR5.
Figures 1 and 2. Fusion results with CCR5 and CCR2b are included (B) Fusion of QT6 cells expressing CD4 and the indicated cofactor
for reference. or chimeric molecules with HeLa cells expressing the JR-FL or 89.6
env proteins was determined using the luciferase reporter assay.
Fusion results obtained with CCR5, CCR2b, and C25-06 are includedmight not reveal its true role in cofactor function if as-
for reference.
sayed on its normal, functionally redundant background.
We therefore constructed a series of chimeric molecules
in which the truncated amino-terminal domains of CCR5 play important roles in governing cofactor function, that
the ability of JR-FL to utilize the CCR5 amino-terminalwere placed into a CCR2b background (Figure 4A). Chi-
mera C25-21, which contains the N-terminal domain of domain is dependent on amino acids 2–5, and that the
ability of 89.6 to utilize the CCR5 amino-terminal domainCCR5 truncated by four residues in a CCR2b back-
ground, supported fusion by 89.6 but not by JR-FL is dependent upon residues 6–9 of CCR5. Further trun-
cations of the CCR5 N-terminus on a CCR2b back-(Figure 4B). This was somewhat surprising, since the
identical truncation in a CCR5background (C25-17) sup- ground did not give rise to active cofactors (data not
shown).ported fusion by both JR-FL and 89.6. Removal of an
additional four residues (C25-22) abolished cofactor To identify the minimal portion of the CCR5 amino
terminus capable of conferring cofactor function tofunction for both89.6 and JR-FL, even though the identi-
cal truncation in a CCR5 background (C25-18) sup- CCR2b, three additional chimeras were constructed
(Figure 4A). We found that substitution of the first 20ported fusion by both viral env proteins. While it is possi-
ble that chimera C25-22 may not be expressed on the residues of CCR2b with those from CCR5 (C25-28) sup-
ported fusion by both JR-FL and 89.6, while the recipro-cell surface, we note that the truncation itself is tolerated
(C25-18), making it more likely that C25-22 is delivered cal chimera containing the first 20 residues of CCR2b
in a CCR5 background (C25-25) supported fusion by JR-to the plasma membrane. Therefore, for both JR-FL and
89.6, N-terminal truncations that otherwise have no ef- FL alone (Figure 4B). The inability of C25-25 to support
fusion by 89.6 was surprising, since chimera C25-01,fect oncofactor function inCCR5 actually prevent cofac-
tor usage in a CCR2b background. These findings indi- which contained the entire CCR2b amino terminus and
first transmembrane domain in a CCR5 background,cate that regions other than the amino terminus of CCR5
CCR5 Determinants of Cofactor Specificity
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Figure 6. N-Linked Carbohydrate Processing of CCR2b, CCR5, and
Nonfunctional Chimeras
QT6 or BSC-1 cells expressing the indicated receptors or chimeras
containing the HA antigenic tag on either the amino terminus (n) or
carboxyl terminus (c) were lysed and processed for endoglycosi-
dase F andH digestion as in Experimental Procedures. The reactions
were then subjected to SDS–PAGE in the presence of 4 M urea,
transferred to PVDF, and Western blotted with the MAb 12CA5,
which detects the HA-tag. The top panel shows endo F digestion,
and the bottom panel shows endo H digestion. (2), mock-treated
sample; (1), enzyme-treated sample. The mobilities of the indicated
molecular weight standards are shown on the left.
Figure 5. Chimeras with Multiple Domain Substitutions
(A) The structures of six chimeras containing multiple domain substi- the first extracellular loops of CCR5 with the homolo-
tutions are depicted, along with their ability to support fusion by gous CCR2b domains (C25-02) supported fusion by 89.6
JR-FL and 89.6. but not by JR-FL. This result indicated that the first
(B) Fusion of QT6 cells expressing CD4 and the indicated cofactor
extracellular loop, in conjunction with the amino-termi-or chimera with HeLa cells expressing the JR-FL or 89.6env proteins
nal domain, plays an important role in governingwas determined using the luciferase reporter assay. Fusion results
M-tropic cofactor function. While JR-FL can toleratewith CCR5 and CCR2b are included for reference.
substitution of either the amino-terminal domain or first
extracellular loop of CCR5 with the homologous CCR2b
regions, it cannot tolerate substitution of both. Thus,did support 89.6 fusion. These results show that, while
in the presence of the CCR5 amino-terminal domain,complete substitution of the amino-terminal domain of
multiple changes in the first, second, and third extracel-CCR5 with that from CCR2b is tolerated by both viruses,
lular loops are well tolerated (C25-05, C25-13).partial domain substitutions within the amino-terminal
Several chimeric molecules failed to support fusion bydomain sometimes (C25-25), but not always (C25-26),
either 89.6 or JR-FL, including C25-08, which containedfail to support fusion. Partial domain substitutions may
both the amino-terminal domain and the first extracellu-alter the conformation of the amino-terminal domain or
lar loop of CCR5. To determine whether these chimericperhaps affect the way in which it interacts with the
molecules were processed normally, we assessed theirextracellular loops.
glycosylation states. An antigenic tag corresponding to
a sequence nine amino acids long and derived from
influenza hemagglutinin (HA) was placed at the amino orThe Role of Extracellular Loop Domains
in Cofactor Function carboxyl terminus of CCR5, CCR2b, and three chimeric
molecules that failed to support membrane fusion: C25-The chimeras described above implicated both the
amino terminus of CCR5 as well as one or more addi- 08, C25-12, and C25-11. The tagged versions of CCR5
and CCR2b supported membrane fusion by 89.6, indi-tional domains as playing important roles in cofactor
function. In order to assess the contribution of other cating that they are transported to the cell surface. QT6
cells expressing the indicated receptor were lysed, anddomains in CCR5 to cofactor function, chimeras con-
taining multiple domain substitutions were constructed aliquots were digested with endoglycosidase F (endo
F) to remove N-linked carbohydrate chains. Fusin-HA(Figure 5A). As shown in Figure 3B, we found that substi-
tution of the CCR5 amino-terminal domain with that from was also examined, since we have previously shown
that it contains at least one N-linked carbohydrate chainCCR2b did not affect cofactor function, even though
several chimeric and mutant molecules (C25-06, C25- (Berson et al., 1996). We found that CCR2b was N-glyco-
sylated (Figure 6), indicating that the single N-linked19, C25-20, C25-21) clearly showed that the amino-ter-
minal domain of CCR5 plays an important role in sup- consensus site in the CCR2b amino-terminal domain is
utilized. However, digestion of CCR5 with endo F failedporting env-mediated membrane fusion. However, we
found that substitution of both the amino-terminal and to increase its mobility in SDS–PAGE, indicating that it
Cell
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or very similar fashion, but one that is distinct from the
dual-tropic 89.6 strain.
Discussion
The entry of HIV-1 into target cells involves interactions
with the primary virus receptor, CD4, and one or more
cofactors (Broder et al., 1993; Alkhatib et al., 1996; Ber-
son et al., 1996; Choe et al., 1996; Deng et al., 1996;
Doranz et al., 1996; Dragic et al., 1996; Feng et al., 1996).
The specific type of cofactor used is a major determinant
of viral tropism. Thus, HIV-1 strains adapted for growth
on transformed T cell lines use a seven-transmembrane
domain receptor, Fusin (Berson et al., 1996; Choe et al.,
Figure 7. Different M-Tropic env Proteins Utilize CCR5/2b Chimeras
1996; Deng et al., 1996; Dragic et al., 1996; Feng et al.,in the Same Way
1996), that is expressed at high levels in T cell lines
QT6 cells expressing CD4 and the indicated wild-type or chimeric
(Federsppiel et al., 1993; Loetscher et al., 1994). Whilecofactor were mixed with HeLa cells expressing the indicated
some primary virus isolates also exhibit the capabilityM-tropic env protein. Fusion was determined as in the previous
of infecting transformed T cell lines, such T-tropic vi-figures.
ruses do not appear to play a significant role in virus
transmission and often cannot be recovered from HIV-1
positive individuals. Instead, most primary virus isolatesis not N-glycosylated. Chimeric molecules containing
fail to infect transformed T cell lines, though they infectthe CCR2b amino-terminal domain were N-glycosylated
primary macrophages and primary T cells efficiently.as well. Migration of chimera C25-08 was not affected
These M-tropic virus strains are responsible for sexualby endo F digestion, consistent with the fact that it does
transmission of HIV-1 and are the prevalent virus typenot contain N-linked consensus sequences.
isolated after seroconversion and during the asymptom-To determine whether the glycosylated receptors
atic portion of the disease (A˚sjo¨ et al., 1986; Tersmettewere processed normally, we subjected aliquots of cell
et al., 1988, 1989; Schuitemaker et al., 1991, 1992; Rooslysates to digestion with endoglycosidase H (endo H).
et al., 1992; Conner et al., 1993). With time, both dual-We found that both Fusin and CCR2b were largely resis-
tropic and T-tropic viruses emerge in some individuals,tant to endo H digestion, indicating that both receptors
with dual-tropic viruses perhaps representing an inter-were transported through theGolgi apparatus.However,
mediate phenotype (Tersmette et al., 1988; Collman etchimeras C25-12 and C25-11 were completely or largely
al., 1992).sensitive to endo H digestion, suggesting that these
Recently, CCR5, a chemokine receptor that bindsmolecules were not transported to the Golgi and cell
RANTES, MIP-1a, and MIP-1b (Samson et al., 1996), hassurface. Thus, the failure of C25-12 and C25-11 to sup-
been shown to be the principle M-tropic virus entryport fusion by HIV-1 env proteins can be attributed to
cofactor (Alkhatib et al., 1996; Choe et al., 1996; Denga transport defect. It is interesting tonote that, of the five
et al., 1996; Doranz et al., 1996; Dragic et al., 1996). Thechimeric molecules in this study that failed to function as
identification of CCR5 as the major entry cofactor forentry cofactors, four contained the second extracellular
M-tropic viruses was aided by its homology (z30%) toloop of CCR2b, a region of the receptor that contains
Fusin and by observations that RANTES, MIP-1a, andan unpaired Cys residue not present in CCR5. Since
MIP-1b are the major viral suppressive factors secretedunpaired Cys residues often form inappropriate disulfide
by CD81 cells (Cocchi et al., 1995) and that lymphocytesbonds in the ER (Doms et al., 1993), chimeric receptors
from some exposed, uninfected individuals secrete highcontaining the secondextracellular loop of CCR2b might
levels of these chemokines (Dragic, 1996; Paxton etbe at greater risk for misfolding and retention in the ER.
al., 1996). Most M-tropic virus strains studied thus far
appear to exclusively use CCR5 as an entry cofactor,
though the number of virus strains for which cofactorClade B M-Tropic Strains Utilize Similar
CCR5 Domains usage has been studied is small, especially viruses from
other clades. It is clear, however, that some virus iso-Our studies indicated that the M-tropic env protein de-
rived from JR-FL and the dual-tropic 89.6 env protein lates can use alternative chemokine receptors as entry
cofactors (Choe et al., 1996; Doranz et al., 1996). Theexhibited differences in their abilities to utilize chimeric
and mutant CCR5 molecules. To determine whether vi- dual-tropic strain 89.6 is remarkably promiscuous: in
addition to CCR5, it can use Fusin and the chemokinerus strains with the same tropism also exhibited differ-
ences in their use of CCR5, two additional M-tropic receptors CCR3 and CCR2b as entry cofactors (Doranz
et al., 1996), suggesting that interactions between vi-viruses were tested for their abilities to utilize a subset
of the chimeric molecules, including C25-01, C25-06, ruses and chemokine receptors will be dependent upon
conserved, conformational elements.C25-21, C25-17, C25-18, and C25-19. As shown in Fig-
ure 7, no differences were observed between the differ- Identifying regions in CCR5 and other viral cofactors
that are important for viral entry will be important forent virus strains, indicating that the M-tropic viruses JR-
FL, ADA, and SF162 interact with CCR5 in an identical understanding the molecular basis of viral tropism and
CCR5 Determinants of Cofactor Specificity
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Figure 8. Proposed Membrane Topography
of CCR5
The amino acid sequence of CCR5 is de-
picted. Extracellular Cys residues are indi-
cated by bars, and the single N-linked glyco-
sylation consensus site is indicated by an
asterisk. Residues that are identical to those
in CCR2b are indicated by dark shading,
while highlyconservative substitutions are in-
dicated by light shading. The locations of the
restriction sites used to generate the chimeric
molecules are shown.
may assist in the design of novel antiviral compounds. important for cofactor activity, since the N-terminal do-
main of CCR5 could be replaced with the correspondingThe approach we took to identify functionally important
CCR5 domains involved the construction of chimeras region from CCR2b and still function as an M-tropic
cofactor. As a consequence, changes in the CCR5between CCR5 and CCR2b and mutagenesis of the
CCR5 amino-terminal domain. CCR2b is expressed in amino-terminal domain that might otherwise affect co-
factor function might go unobserved when assayed onmonocytes, binds the CC chemokines MCP-1 and
MCP-3 (Charo et al.,1994; Franci et al., 1995),and shares the functionally redundant CCR5 background. Indeed,
additional complexities were observed when CCR576% amino acid identity with CCR5. Due to their struc-
tural similarity, we anticipated that a high proportion amino-terminal mutations were examined in a CCR2b
background. Thus the ability of M-tropic env proteinsof chimeras generated between these two molecules
would be transported to the cell surface. In fact, at least to use CCR5 was dependent on residues 2–5 of the
N-terminal domain, while 89.6 was strongly dependent18 of the 24 chimeric and mutant molecules studied
here were expressed on the cell surface as judged by on residues 6–9. Therefore, the amino-terminal domain
of CCR5 plays an important role in cofactor functiontheir ability to support env-mediated membrane fusion.
A further advantage of using CCR2b as a template for for both M- and dual-tropic viruses, though there are
differences in how each virus type utilizes this domain.studying functionally important CCR5 domains is that it
is used by 89.6 as an entry cofactor, making it likely that Our results also implicate the first extracellular loop of
CCR5 as being important for cofactor function, althoughmost chimeric molecules would function as cofactors
for this viral env protein. We found four chimeric or like the amino-terminal domain it is not absolutely nec-
essary: the first loop of CCR5 can be replaced by themutant receptors that functioned for 89.6 but not for
JR-FL and three that functioned for JR-FL but not for corresponding region in CCR2b without loss of activity.
The 14-residue-long first extracellular loop contains a89.6. Thus we were able to detect functional cofactors
that would have been scored as negative had we used conserved Cys residue thought to form a disulfide bond
with a Cys residue in the secondextracellular loop, alongonly one type of env protein. Finally, the transmembrane
and cytoplasmic loops of CCR5 and CCR2b are highly with three charged residues, none of which are con-
served between CCR5 and CCR2b. Chimera 25-02 is theconserved (95% and 96% including highly conservative
substitutions, respectively), whereas the extracellular most informativewith regards to the potential function of
this domain. Replacement of both the amino-terminaldomains share only 45% amino acid identity (Figure 8).
Thus the extracellular domains are likely to play the domain and the first extracellular loop (C25-02) resulted
in a chimeric molecule that could be used by 89.6 butmajor role in determining the cofactor phenotypes ex-
hibited by the chimeric molecules. not by M-tropic viruses as a fusion cofactor. By contrast,
double substitution of the first and second loops (chi-Our results indicate that the amino terminus of CCR5
plays an important role invirus entry. The amino-terminal mera C25-05) or the first and third loops (C25-13) of
CCR5 with those from CCR2b was tolerated, as longdomain of CCR5 was the only region that, when intro-
duced into CCR2b, conferred M-tropic cofactor activity as the CCR5 amino-terminal domain was present. We
found that M-tropic viruses could tolerate substitutionto the resulting chimera. Further analysis showed that
the first 20 residues of CCR5, the region of CCR5 that of either the N-terminal domain or the first extracellular
loop of CCR5 with the corresponding CCR2b domainsis most highly divergent from CCR2b (Figure 8), were
sufficient for conferring M-tropic cofactor activity to but not of both simultaneously.
We also constructed chimeras to test the role of theCCR2b. However, other regions of CCR5 must also be
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second and third extracellular loops in cofactor function. that relatively subtle changes in chemokine structure
can result in a different receptor-binding profile. Substi-The second extracellular loop is highly divergent be-
tween CCR5 and CCR2b, with only 11 of 30 residues tution of Leu-25 in IL8 with Tyr enables this CXC chemo-
kine to bind to the CC chemokine receptor CCR1 (Lusti-being conserved, including a Cys residue and three se-
quential charged amino acids. Introduction of the sec- Narasimhan et al., 1996; Wells et al., 1996), while deletion
of the RANTES amino terminus enables it to bind toond loop from CCR5 into CCR2b failed to confer
M-tropic cofactor function, while substitution of the sec- multiple chemokine receptors (Gong et al., 1996). Al-
though the identification of multiple functionally impor-ond loop of CCR5 with that from CCR2b failed to prevent
M-tropic env-mediated membrane fusion. Thus, the sec- tant regions in CCR5 for cofactor activity suggests that
structurally complex interactions may occur betweenond loop appears to play little role in cofactor specificity,
at least when tested in either a CCR5 or CCR2b back- CCR5 and M-tropic viruses, relatively minor changes in
env structure could result in altered coreceptor utiliza-ground. However, we cannot rule out the possibility that
residues conserved between CCR5 and CCR2b partici- tion that would be important for virus evolution. Further
mutagenesis studieswill aid in better defining the criticalpate in some way.
The third extracellular loop is the most highly con- determinants for cofactor activity and assist in the de-
sign of novel antiviral compounds that may be capableserved ectodomain region between CCR5 and CCR2b,
with 17 of 23 residues being identical, including all four of blocking both M- and dual-tropic isolates.
charged residues. Since introduction of the third extra-
Experimental Procedurescellular loop of CCR5 into a CCR2b background was not
sufficient for M-tropic cofactor activity (C25-03), these
CCR5/CCR2b Hybrid Constructsconserved residues by themselves are clearly not suffi-
The CCR5 construct has been described previously (Samson
cient for cofactor function. However, due to their similar- et al., 1996). The coding region of CCR2b was amplified by PCR
ity, the fact that replacement of CCR5’s third loop with using NTerm2 (59-TCGAGGATCCACAACATGCTGTCCACA-39) and
that from CCR2b had no effect on cofactor function Cterm2 (59-CTGATCTAGACCTCGTTTTATAAACCAG-39) as primers
and cloned between the BamHI and XbaI sites of pcDNA3. The AflIIshould not be taken as evidence that this region is not
restriction site was introduced by site-directed mutagenesis in aimportant. Site-directed mutagenesis or construction of
region corresponding to the end of the first transmembrane regionchimeras between more distantly related molecules will
(Figure 8). Mutagenesis was done by PCR using primers Nterm5
be required to more fully understand the role that the and Afl2R5 (59-AGTCATGCTCTTAAGCCTTTTGCAG-39) as well
third extracellular loop plays in virus entry. In fact, the as Afl2F5 (59-CTGCAAAAGGCTTAAGAGCATGACT-39) and Cla1R
high degree of conservation of this region, the use of (59-AGCCAGGTACCTATCGATTGTCAG-39) for CCR5, and Nterm2
and Afl2R2 (59-AGTCAAGCACTTAAGCTTTTTGCAG-39) as well asboth receptors as cofactors by 89.6 (Doranz et al., 1996),
Afl2F2 (59-CTGCAAAAAGCTTAAGTGCTTGACT-39) and Cla1R forand studies with the IL8 receptor (Hebert et al., 1993;
CCR2b. Products were cleaved by either BamHI and AflII or AflIIHoruk, 1994) all suggest that residues in the third loop
and ClaI and were cloned by trimolecular ligation in pcDNA3-CCR5
may help regulate cofactor function. or in pcDNA-CCR2b cleaved with BamHI and ClaI. All constructions
Relatively little is known about the structure–function involving PCR were verified by sequencing. The various hybrid com-
relationships of chemokine receptors and their ligands. binations (C25-01 to C25-14) were performed by transferring restric-
tion fragments flanked by the common BamHI, AflII, ClaI, EcoRI,However, a predominant theme emerging from studies
and XbaI sites between the CCR5 and CCR2b constructs.in this area is that the N-terminus of these molecules
plays a major role in specificity and function. The amino
Deletion Mutantsterminus of the Duffy antigen, a receptor that binds both
The deletion mutants of the CCR5 N-terminal extracellular region
CC and CXC chemokines, plays a critical role in ligand (C25-17 to C25-20) were constructed by generating PCR fragments,
binding (Zhao-hai et al., 1995), and the N-terminal region using Afl2R5 as common reverse primer and N5D4 (59-TCGAGGATC
of the IL8 receptor is a major determinant in defining CAAGATGTCAAGTCCAATCTAT-39), N5D8 (59-TCGAGGATCCAAGA
TGTATGACATCAATTAT-39), N5D12(59-TCGAGGATCCAAGATGTATligand specificity (Hebert et al., 1993; Horuk, 1994; Ahuja
TATACATCGGAG-39), andN5D16 (59-TCGAGGATCCAAGATGGAGCet al., 1996). Alanine-scanning mutagenesis of IL8-RA
CCTGCCAAAAA-39), respectively, as forward primers. The PCRidentified three charged residues important for ligand
products were cleaved with BamHI and AflII and cloned into the
binding, including two in the third extracellular loop of CCR5 construct cleaved with the same enzymes. Amplified seg-
the receptor (Hebert et al., 1993). The amino-terminal ments were verified by sequencing. The deleted CCR5 N-terminal
domains of Fusin (Feng et al., 1996) and CCR5 also segments were transferred onto the CCR2b background (C25-21 to
C25-24) by cloning BamHI/AflII fragments into the pcDNA3-CCR2bappear to be important for HIV env fusion activity. How-
construct.ever, as is the case for the IL8 receptor, our findings
indicate that multiple regions of CCR5 are important for
Other ConstructsHIV env cofactor activity, including the N-terminus and
N- and C-terminally tagged constructs were made by PCR incorpo-
first extracellular loop. The involvement of multiple ex- ration of the 12CA5 epitope of the influenza hemagglutinin protein
tracellular domains of CCR5 in virus entry is not surpris- (HA). N-terminal tagging of CCR5 involved the use of the NTag5
ing. By analogy with other seven transmembrane do- forward primer (59- TCGAGGATCCAAGATGTACCCCTACGACGTG
CCCGACTACGCCGGGCCCGGGGATTATCAAGTGTCA-39), insert-main receptors, conserved disulfide bonds (Figure 8)
ing the peptide YPYDVPDYAGPG immediately after the initial methi-are likely to bring the extracellular domains of CCR5 in
onine, and the Afl2R5 reverse primer. The PCR product was cleavedclose proximity to one another (Horuk, 1994; Murphy,
by EcoRI and AflII and cloned into the pcDNA3-CCR5 construct.
1994). The HA tag was also introduced at the C-terminus of both CCR5
We have shown a distinction between M- and dual- and CCR2b, using a similar approach.
tropic HIV virus strains in their use of CCR5 as a fusion The CCR5/CCR2b N-terminal hybrids (C25-26 and C25-28) were
constructed using the Nterm5 and N5>2R1 (59-TCAAATTTATGACAcofactor. Studies with several chemokines have shown
CCR5 Determinants of Cofactor Specificity
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